{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:33:54Z","timestamp":1794717234543,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116686","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:34:50Z","timestamp":1774283690000},"page":"116686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1007-0112","authenticated-orcid":false,"given":"Sarah","family":"Blocker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-9127","authenticated-orcid":false,"given":"Courtney C.","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0233-4009","authenticated-orcid":false,"given":"Alexander","family":"Olinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Bortka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-8528","authenticated-orcid":false,"given":"Allison","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7928-5157","authenticated-orcid":false,"given":"Jacob","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5401-3268","authenticated-orcid":false,"given":"Kori","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-9378","authenticated-orcid":false,"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-3287","authenticated-orcid":false,"given":"Ty","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-6705","authenticated-orcid":false,"given":"Prakash","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-6187","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Mullangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-1855","authenticated-orcid":false,"given":"Manidhar Reddy","family":"Lekkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-7508","authenticated-orcid":false,"given":"Timothy","family":"Schieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.116686_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"21","key":"10.1016\/j.ejca.2026.116686_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2026.116686_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116686_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10238-024-01520-y","article-title":"Bispecific antibodies in clinical practice: understanding recent advances and current place in cancer treatment landscape","volume":"25","author":"Verma","year":"2024","journal-title":"Clin Exp Med"},{"issue":"22","key":"10.1016\/j.ejca.2026.116686_bib5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.116686_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116686_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2478\/v10019-012-0007-1","article-title":"Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting","volume":"46","author":"Lekic","year":"2012","journal-title":"Radio Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116686_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.21037\/tlcr-2024-1091","article-title":"Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy","volume":"14","author":"Kaira","year":"2025","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2026.116686_bib9","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1007\/s12094-025-03918-w","article-title":"Treatment patterns and survival outcomes in patients with small-cell lung cancer following failure of first-line platinum-based chemotherapy","volume":"27","author":"Chiang","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116686_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12890-025-03625-w","article-title":"Factors affecting survival and prognosis in extensive stage small cell lung cancer","volume":"25","author":"Erciyestepe","year":"2025","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.116686_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"10.1016\/j.ejca.2026.116686_bib12","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"27","key":"10.1016\/j.ejca.2026.116686_bib13","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2026.116686_bib14","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.ejca.2026.116686_bib15","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell\u2013based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2026.116686_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"19","key":"10.1016\/j.ejca.2026.116686_bib17","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.ejca.2026.116686_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ejca.2026.116686_bib19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jtho.2025.02.023","article-title":"Rapid intracranial response with tarlatamab in patients with untreated brain metastases from SCLC-a real-world case series: case report","volume":"20","author":"Zhang","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2026.116686_bib20","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ejca.2026.116686_bib21","article-title":"Impatient for outpatient: operationalizing bispecific antibodies for multiple myeloma in the ambulatory setting","volume":"21","author":"Olivieri","year":"2024","journal-title":"JCO Oncol Pr"},{"issue":"17","key":"10.1016\/j.ejca.2026.116686_bib22","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.3390\/cancers14174333","article-title":"The efficacy of PD-1\/PD-L1 inhibitors in patients with liver metastasis of non-small cell lung cancer: a real-world study","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2026.116686_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","article-title":"The liver-immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2026.116686_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gutjnl-2023-330024","article-title":"Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy","volume":"73","author":"Green","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejca.2026.116686_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-017-2510-0","article-title":"Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy","volume":"134","author":"Bernhardt","year":"2017","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116686_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116686_bib27","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.2147\/CMAR.S302928","article-title":"\"High Tumor Burden\" in metastatic non-small cell lung cancer: defining the concept","volume":"13","author":"Gomez","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2026.116686_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.111198","article-title":"Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy","volume":"170","author":"Kifjak","year":"2024","journal-title":"Eur J Radio"},{"issue":"5","key":"10.1016\/j.ejca.2026.116686_bib29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116686_bib30","first-page":"419","article-title":"Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma","volume":"31","author":"Shouval","year":"2025","journal-title":"Transpl Cell Ther"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2026.116772","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:16:03Z","timestamp":1775693763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S0959804926004661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116686","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116686"}}